Rheumatic and Immune Disease

Clinical analysis of fifteen patients with systemic juvenile idiopathic arthritis associated lung disease

  • Lingzhi QIU ,
  • Yayuan ZHANG ,
  • Le MA ,
  • Zhidan FAN ,
  • Na HUANG ,
  • Haiguo YU
Expand
  • Department of Rheumatology and Immunology, Children’s Hospital of Nanjing Medical University, Nanjing 210008, Jiangsu, China

Received date: 2022-01-17

  Online published: 2022-10-12

Abstract

Objective To investigate the clinical features, imaging manifestations, treatment response and prognosis of children with systemic juvenile idiopathic arthritis associated lung disease (sJIA-LD). Methods The clinical data of 15 children with sJIA-LD were retrospectively analyzed, and the clinical characteristics, laboratory parameters, imaging changes and treatment prognosis were summarized. Results There were 7 boys and 8 girls in current study and the average age was 7 years. The common clinical symptoms were fever (15 cases), joint swelling and pain (12 cases), cough (12 cases), rash (11 cases), lymph node enlargement (9 cases), serositis (8 cases), hepatosplenomegaly (8 cases), shortness of breath (7 cases), chest pain (2 cases) and abdominal pain (1 case). Seven patients were complicated with macrophage activation syndrome (MAS). All the 15 children underwent chest high-resolution CT examination, and the results showed strip or patchy shadow in 15 children, consolidation shadow in 3 children, mesh shadow in 2 children, nodular shadow, calcification shadow and atelectasis in 1 child each. The commonest lesion site was the left lower lobe of the lung (13/15). The imaging findings revealed 9 cases of organizing pneumonia, 5 cases of non-specific interstitial pneumonia, and 1 case of usual interstitial pneumonia. All the 13 patients were treated with non-steroid anti-inflammatory drug and glucocorticoids. In the diagnosis of sJIA-LD, 8 cases were treated with slow-acting antirheumatic drugs, including 3 cases of cyclosporine, 4 cases of methotrexate and 1 case of cyclophosphamide. Eight children were treated with tocilizumab. The condition of 12 children improved, and chest high-resolution CT showed improvement. One patient had lung disease progression and eventually died. Conclusion The early clinical symptoms of sJIA-LD are mild but the mortality is high. The high-resolution CT is helpful for early diagnosis.

Cite this article

Lingzhi QIU , Yayuan ZHANG , Le MA , Zhidan FAN , Na HUANG , Haiguo YU . Clinical analysis of fifteen patients with systemic juvenile idiopathic arthritis associated lung disease[J]. Journal of Clinical Pediatrics, 2022 , 40(10) : 750 -754 . DOI: 10.12372/jcp.2022.22e0104

References

[1] Woo P. Systemic juvenile idiopathic arthritis: diagnosis, management, and outcome[J]. Nat Clin Pract Rheumatol, 2006, 2(1): 28-34.
[2] Petty RE, Southwood TR, Manners P, et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis:second revision, Edmonton, 2001[J]. J Rheumatol, 2004, 31(2): 390-392.
[3] Gurion R, Lehman TJ, Moorthy LN. Systemic arthritis in children: a review of clinical presentation and treatment[J]. Int J Inflam, 2012, 2012: 271569.
[4] Lomater C, Gerloni V, Gattinara M, et al. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years[J]. J Rheumatol, 2000, 27(2): 491-496.
[5] Lang BA, Schneider R, Reilly BJ, et al. Radiologic features of systemic onset juvenile rheumatoid arthritis[J]. J Rheumatol, 1995, 22(1): 168-173.
[6] Schulert GS, Yasin S, Carey B, et al. Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors[J]. Arthritis Rheumatol, 2019, 71(11): 1943-1954.
[7] 中国医师协会儿科医师分会风湿免疫学组, 中国儿童免疫与健康联盟, 中国实用儿科杂志编辑委员会. 儿童风湿性疾病相关巨噬细胞活化综合征诊断与治疗专家共识之一——总论篇[J]. 中国实用儿科杂志, 2020, 35(11): 825-831.
[8] Kimura Y, Weiss JE, Haroldson KL, et al. Childhood Arthritis Rheumatology Research Alliance Carra Net Investigators. Pulmonary hypertension and other potentially fatal pulmonary complications in systemic juvenile idiopathic arthritis[J]. Arthritis Care Res (Hoboken), 2013, 65(5): 745-752.
[9] Russo RA, Katsicas MM. Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome[J]. J Rheumatol, 2013, 40(3): 329-334.
[10] Iriguchi S, Kikuchi N, Kaneko S, et al. T-cell-restricted T-bet overexpression induces aberrant hematopoiesis of myeloid cells and impairs function of macrophages in the lung[J]. Blood, 2015, 125(2): 370-382.
[11] Ter Haar NM, Swart JF, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five-year follow-up study[J]. Arthritis Rheumatol, 2019, 71(7): 1163-1173.
[12] Saper VE, Chen G, Deutsch GH, et al. Childhood Arthritis and Rheumatology Research Alliance Registry Investigators. Emergent high fatality lung disease in systemic juvenile arthritis[J]. Ann Rheum Dis, 2019, 78(12): 1722-1731.
[13] Nigrovic PA. Storm warning: lung disease in systemic juvenile idiopathic arthritis[J]. Arthritis Rheumatol, 2019, 71(11): 1773-1775.
Outlines

/